UBS Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

UBS Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,000	Closed	-$914K	–	8502
2017 Q4	$914K	Hold	20,000	–	–	﹤0.01%	3856
2017 Q3	$897K	Hold	20,000	–	–	﹤0.01%	3795
2017 Q2	$598K	Hold	20,000	–	–	﹤0.01%	3996
2017 Q1	$444K	Buy	+20,000	New	+$429K	﹤0.01%	4123

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS Group's JUNO Position: Q1 2018 in Review

UBS Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 68,425 shares — an estimated $3.13M sold.

UBS Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $8.17M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

UBS Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
UBS Group sold 68,425 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.13M.
UBS Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
UBS Group's Juno Therapeutics, Inc. position peaked at $8.17M in Q1 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.